Breast Cancer Clinical Trials

Find Breast Cancer Clinical Trials Near You

To Assess the Impact of Cancer Treatment-Induced Cognitive Impairment on Chronic Pain in Patients With Breast Cancer Over a One-year Period.

Status: Recruiting
Location: See location...
Intervention Type: Behavioral
Study Type: Observational
SUMMARY

Objective: To evaluate the influence of cognitive impairment, defined as a significant alteration in the Global Composite Score (GCS), measured 6 months (±1 week) after completion of chemotherapy, on chronic pain over a one-year period following inclusion. Chronic pain is defined as persistent pain intensity ≥4. The GCS includes 8 measures derived from cognitive tests assessing long-term memory, inhibition, cognitive flexibility, verbal fluency (categorical and phonemic), nonverbal fluency, working memory, and phasic attention. The primary endpoint is the comparison of the percentage of patients with chronic pain between patients with and without cognitive impairment at 6 months after chemotherapy completion (T3). Secondary

Objectives: 1. Compare the percentage of chronic pain in patients with and without cognitive impairment at T2 (±2 weeks after chemotherapy completion), based on persistent pain intensity ≥4/10 on the Brief Pain Inventory (BPI). 2. Compare chronic pain characteristics and pain-related disability between patients with and without cognitive impairment at T2 and T3, including etiology, incidence, severity, localization, and disability. Pain characteristics will be assessed using the BPI, McGill Pain Questionnaire, DN4, NPSI, and a body diagram. 3. Compare, at T2 and T3, cognitive test scores used to calculate the GCS in patients with chronic pain to determine whether impairment in specific cognitive functions has a greater influence on chronic pain. 4. Compare the percentage of chronic pain in patients with cognitive complaints versus those without cognitive complaints at T2 and T3. Cognitive complaints will be assessed using the FACT-Cog and WMQ questionnaires. 5. Evaluate the influence of cognitive impairment on pain coping strategies at T2 and T3 using the Coping Strategies Questionnaire (CSQ). 6. Evaluate the influence of cognitive impairment on fatigue, anxiety, depressive symptoms, and sleep disturbances in patients with and without chronic pain at T2 and T3. Fatigue will be assessed using the MFI, sleep disturbances using the PSQI, and anxiety/depressive symptoms using the HADS. Assessments will be performed at the following time points: T1: before chemotherapy, but after surgery T2: after completion of chemotherapy (± 2 weeks) T3: 6 months after completion of chemotherapy (± 1 week)

Eligibility
Participation Requirements
Sex: Female
Minimum Age: 35
Maximum Age: 65
Healthy Volunteers: f
View:

• Female patients aged 35 to 65 years

• Signed informed consent

• Affiliated with the French social security system or entitled beneficiary

• Able to read and understand French

• Willing to participate and able to comply with study procedures

• Diagnosed with non-metastatic, hormone receptor-positive breast cancer

• No prior chemotherapy exposure

• Adjuvant treatment setting after surgery)

• Receiving the same treatment sequence: surgery, chemotherapy (anthracycline- and taxane-based regimens), radiotherapy, and hormone therapy.

Locations
Other Locations
France
Inserm U 987
RECRUITING
Boulogne-billancourt
Contact Information
Primary
Didier Bouhassira, MD, PhD
didier.bouhassira@inserm.fr
01 49 09 45 56
Backup
Sophie Baudic, PhD
sophie.baudic@inserm.fr
06 15 43 31 02
Time Frame
Start Date: 2026-01-09
Estimated Completion Date: 2028-03
Participants
Target number of participants: 182
Treatments
Cognitive statut
with or without cogntive deficits
Related Therapeutic Areas
Sponsors
Collaborators: Institut National de la Santé Et de la Recherche Médicale, France
Leads: Nadine ATTAL

This content was sourced from clinicaltrials.gov